HIV specialist ViiV Healthcare has announced positive findings from the Phase IIa BANNER proof-of-concept study, looking at its antibody N6LS. 26 October 2022
With the final presentations of this year’s meeting of the European Society of Medical Oncology (ESMO 22) in full swing, there is a lot for the scientific commu 12 September 2022
American drugmaker Eli Lilly has provided updated results from the MONARCH 3 trial, at the annual meeting of the European Society of Medical Oncology (ESMO 22). 12 September 2022
Long-term follow-up results from the PAOLA-1 and SOLO-1 Phase III trials of Lynparza (Olaparib), with or without bevacizumab, have demonstrated clinically meani 9 September 2022
Spanish dermatology company Almirall has provided some detail on the results from a Phase III atopic dermatitis (AD) trial of lebrikizumab. 8 September 2022
Competition for one of the best-selling medicines of all time is gaining traction, with new three-year data for Hadlima (adalimumab-bwwd), a biosimilar of adali 7 September 2022
Belgium’s largest pharma company UCB has announced new three-year results from the BE BRIGHT open-label extension study of bimekizumab. 7 September 2022
Important new data for the antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) have been outlined ahead of their presentation at the annual meet 5 September 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.